Leerink Partners Initiates Coverage On Obsidian Therapeutics with Outperform Rating, Announces Price Target of $32
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Leerink Partners initiates coverage on Obsidian Therapeutics (NASDAQ:OBX) with a Outperform rating and announces Price Target of $32.
Leerink Partners initiates coverage on Obsidian Therapeutics (NASDAQ:OBX) with a Outperform rating and announces Price Target of $32.